

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6094608

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AARON MICHAEL RING	03/06/2017
ROY LOUIS MAUTE	03/06/2017
ANDREW CURTIS KRUSE	03/06/2017
AASHISH MANGLIK	05/09/2017
KENNETH S. LIN	05/16/2017
RECEIVING PARTY DATA	
Name:	AB INITIO BIOTHERAPEUTICS, INC.
Street Address:	244 MERRITT ROAD
City:	LOS ALTOS
State/Country:	CALIFORNIA
Postal Code:	94022
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16866425
CORRESPONDENCE DATA	
Fax Number:	(858)350-2399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8583502300
Email:	cevaristo@wsgr.com, patentedocket@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	47815-701.302
NAME OF SUBMITTER:	CASSIDY K. EVARISTO
SIGNATURE:	/Cassidy K. Evaristo/
DATE SIGNED:	05/06/2020
Total Attachments: 6	
source=47815-701.302 Parent Assignment#page1.tif	

source=47815-701.302 Parent Assignment#page2.tif
source=47815-701.302 Parent Assignment#page3.tif
source=47815-701.302 Parent Assignment#page4.tif
source=47815-701.302 Parent Assignment#page5.tif
source=47815-701.302 Parent Assignment#page6.tif

WHEREAS, the undersigned:

- | | | |
|--|---|---|
| 1. Aaron Michael RING
2253 Williams Street
Palo Alto, CA 94306, US | 2. Roy Louis MAUTE
75 Sheridan Street, #202
San Francisco, CA 94103, US | 3. Andrew Curtis KRUSE
27 Hewlett Street, Unit 3
Roslindale, MA 02131, US |
| 4. Aashish MANGLIK
945 Crane Street
Menlo Park, CA 94025, US | 5. Kenneth S. LIN
P.O. Box 1005
Los Altos, CA 94023, US | |

(hereinafter "Inventor(s)"), have invented certain new and useful improvements in

SIRP Polypeptide Compositions and Methods of Use

- for which a United States patent application is filed on even date herewith;
- for which application serial number 15/157,291 was filed on May 17, 2016, in the United States Patent and Trademark Office;
- for which a PCT application serial number _____ was filed on _____ in the [] Receiving Office of the Patent Cooperation Treaty;
- for which application serial number _____ was filed on _____ in the _____ Patent Office;
- for which an application was filed upon which a United States Patent issued on _____, as U.S. Patent No. _____; or
- for which a PCT application will be filed on or before [] in the [] Receiving Office of the Patent Cooperation Treaty which will

claim priority to [] .

(hereinafter, "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, Ab Initio Biotherapeutics, Inc., a corporation of the State of Delaware, having a place of business at 244 Merritt Road, Los Altos, CA 94022, US, (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Application(s), and the inventions disclosed therein, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patent(s)").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Application(s); (d) in and to said Patent(s) and each and every patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; (f) in and to each and every patent and application filed outside the United States and corresponding to any of the foregoing; and (g) in and to all claims for past, present and future infringement of the Patent(s), including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patent(s).

2. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

4. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.


5. Said Inventor(s) hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.


PATENT ASSIGNMENT

Docket Number 47815-701.201



IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: <u>3/6/2017</u>		Date: _____	_____
	Aaron Michael RING		Roy Louis MAUTE
Date: _____	_____	Date: _____	_____
	Andrew Curtis KRUSE		Aashish MANGLIK
Date: _____	_____		
	Kenneth S. LIN		

RECEIVED AND AGREED TO BY ASSIGNEE: AB INITIO THERAPEUTICS, INC.

Date: 3/9/2017 Signature: 


Name: Kenneth S. Lin
Title: President and Chief Executive Officer

PATENT ASSIGNMENT		Docket Number 47815-701.201
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:		
Date: _____	Date: <u>3/06/17</u>	 _____ Roy Louis MAUTE
_____	_____	_____
Aaron Michael RING	Andrew Curtis KRUSE	Aashish MANGLIK
Date: _____	_____	_____
_____	_____	_____
Kenneth S. LIN		
RECEIVED AND AGREED TO BY ASSIGNEE:		AB INITIO THERAPEUTICS, INC.
Date: <u>3/9/17</u>	Signature:  _____	
	Name: Kenneth S. Lin Title: President and Chief Executive Officer	

PATENT ASSIGNMENT

Docket Number 47815-701.201

IN WITNESS WHEREOF, said inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____	_____	Date: _____	_____
	Aaron Michael RING		Roy Louis MAUTE
Date: <u>3/6/17</u>		Date: _____	_____
	Andrew Curtis KRUSE		Aashish MANGLIK
Date: _____	_____		
	Kenneth S. LIN		

RECEIVED AND AGREED TO BY ASSIGNEE:

AB INITIO THERAPEUTICS, INC.

Date: 3/9/17

Signature: 
Name: Kenneth S. Lin
Title: President and Chief Executive Officer

PATENT ASSIGNMENT

Docket Number 47815-701.201

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Aaron Michael RING

Date: _____
Roy Louis MAUTTE

Date: _____
Andrew Curtis KRUSE

Date: 5/9/2017

Aashish MANGLIK

Date: _____
Kenneth S. LIN

RECEIVED AND AGREED TO BY ASSIGNEE:

AB INITIO THERAPEUTICS, INC.

Date: 5/16/2017

Signature: 
Name: Kenneth S. Lin
Title: President and Chief Executive Officer

PATENT ASSIGNMENT

Docket Number 47815-701.201


IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: _____
Aaron Michael RING

Date: _____
Roy Louis MAUTE

Date: _____
Andrew Curtis KRUSE

Date: _____
Aashish MANGLIK

Date: 5/16/2017

Kenneth S. LIN

RECEIVED AND AGREED TO BY ASSIGNEE:

AB INITIO THERAPEUTICS, INC.

Date: 5/16/2017

Signature: 
Name: Kenneth S. Lin
Title: President and Chief Executive Officer